Tag: Keytruda
Eagle Pharmaceuticals gets Pemfexy FDA approval for NSCLC
Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication for the intravenous medication. Pemfexy in combination ... Read More
Cue Biopharma gets FDA fast track status for CUE-101 in HPV16+ R/M HNSCC
Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of ... Read More
PDS Biotechnology gets FDA fast track status for PDS0101
PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for ... Read More
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been ... Read More
Merck bags EU approval for Keytruda chemo combo therapy for NSCLC
Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum ... Read More
Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors
Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety ... Read More
Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC
Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for ... Read More